Cart
sales@molnova.com
(2S,4S)-Sacubitril
CAS No. 149709-63-7
(2S,4S)-Sacubitril ( Sacubitril Impurity C )
Catalog No. M27052 CAS No. 149709-63-7
(2S,4S)-Sacubitril is a stereoisomer derived from Sacubitril which is a potent NEP inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 448 | Get Quote |
|
| 10MG | 683 | Get Quote |
|
| 25MG | 1161 | Get Quote |
|
| 50MG | 1764 | Get Quote |
|
| 100MG | 2673 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name(2S,4S)-Sacubitril
-
NoteResearch use only, not for human use.
-
Brief Description(2S,4S)-Sacubitril is a stereoisomer derived from Sacubitril which is a potent NEP inhibitor.
-
Description(2S,4S)-Sacubitril is a stereoisomer derived from Sacubitril which is a potent NEP inhibitor.
-
SynonymsSacubitril Impurity C
-
PathwayOthers
-
TargetOther Targets
-
RecptorSARS-CoV-2 3CL
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number149709-63-7
-
Formula Weight430.5
-
Molecular FormulaC24H28NO5 1/2Ca
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C([O-])CCC(N[C@@H](C[C@H](C)C(OCC)=O)CC1=CC=C(C2=CC=CC=C2)C=C1)=O.O=C([O-])CCC(N[C@@H](C[C@H](C)C(OCC)=O)CC3=CC=C(C4=CC=CC=C4)C=C3)=O.[Ca+2]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yuto Unoh, et al. Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. bioRxiv 2022.01.26.477782.
molnova catalog
related products
-
Cromoglicic acid
Cromoglicic acid is a mast cell stabilizer with anti-inflammatory activity that prevents the release of inflammatory chemicals such as histamine, leukotrienes from mast cells.
-
4-QUinolinecarboxami...
4-QUinolinecarboxamide, N-[3-[[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]carbonyl]phenyl]-1,2-dihydro-2-oxo- is an amine.
-
Cuparene
(+)-Cuparene is a bioactive chemical.
